The use of cannabidiol in patients with Lennox-Gastaut Syndrome and Dravet syndrome in the UK Early Access Program: A retrospective chart review study

• Published in: Epilepsy & behavior reports 2024-11, p.100731, Article 100731
• Main Authors: Eltze, Christin, Alshehhi, Shaikha, Ghfeli, Aisha Al, Vyas, Kishan, Saravanai-Prabu, Seeta, Gusto, Gaelle, Khachatryan, Artak, Martinez, Marta, Desurkar, Archana
• Format: Article
• Language: English
• Subjects: Cannabidiol; Clinical practice; Dravet syndrome; Early access program; Lennox-Gastaut syndrome; Seizure
• ISSN: 2589-9864; 2589-9864
• DOI: 10.1016/j.ebr.2024.100731

•Retrospective chart review of CBD use in patients with LGS and DS in a UK EAP.•CBD retention for patients not lost to follow up was 14/19 (74 %) at 12 months.•AESIs were reported in 70 % and 53 % of patients at 6 and 12 months, respectively.•Results on CBD effectiveness and safety are consistent with previous studies. To evaluate clinical outcomes from the UK Early Access Program in patients aged 2–17 years with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) treated with plant-derived highly purified cannabidiol (CBD; Epidyolex®; 100 mg/mL oral solution). Retrospective chart review of data collected from baseline (1 month before CBD treatment initiation) until 12 months’ treatment, CBD discontinuation, death, or loss to follow up. At baseline, all 26 patients enrolled (LGS, n = 17; DS, n = 9; male, 73 %; mean [range] age, 11.8 [3.0–17.0] years) experienced motor seizures; 92 % were taking ≥ 1 antiseizure medication. Median (IQR) CBD dosage at 6 months (6 M; n = 12) was 6.0 (2.7) mg/kg/day, and 12 months (12 M; n = 9) 7.3 (2.1) mg/kg/day. Median (IQR) percentage change from baseline for motor seizures was − 56.7 % (60.7) at 6 M (n = 20), and − 60.0 % (53.3) at 12 M (n = 15). Patients experiencing ≥ 50 % and ≥ 75 % reduction in motor seizures were 13/20 (65 %) and 5/20 (25 %) at 6 M, respectively, and 10/15 (67 %) and 6/15 (40 %) at 12 M, respectively. Mean (SD) motor seizure-free days/month were 1.5 (4.3) at baseline (n = 24, missing data n = 2), 2.4 (6.3) at 6 M (n = 18), and 2.7 (5.5) at 12 M (n = 15). At 12 M, CBD retention for patients with follow-up data was 14/19 (74 %), whilst 7/26 (27 %) were lost to follow up. The number of patients reporting ≥ 1 adverse event of special interest (most common: gastrointestinal) was 14/20 (70 %) and 8/15 (53 %) at 6 M and 12 M, respectively. Results demonstrate a reduction in motor seizures and a safety profile consistent with previous studies.